Mark Proctor

Mark Proctor CBE is currently the General Manager of AstraZeneca’s R&D and Operations site in Liverpool (UK), which is primarily responsible for the development, manufacture, and release of the sterile bulk drug substance for the seasonal Live Attenuated Influenza Vaccine. Prior to this Mark has held several senior roles across biopharmaceutical development, global supply chain, and site technical operations, and he led the Global Supply Team responsible for setting up and launching the Oxford/AstraZeneca vaccine for SARS-CoV-2 in the UK and Internationally.

Mark is a Fellow of the Institute of Chemical Engineers, holds a Master’s degree in Biochemical Engineering (UCL), and an Executive MBA (Bayes Business School, London). He was awarded a CBE in the 2021 Queen’s Birthday Honours in recognition of his services to the Covid-19 response.